Product development

Sophiris is focused on the development of PRX302, a late-stage, highly targeted treatment for the symptoms of benign prostatic hyperplasia (BPH or enlarged prostate). PRX302, currently in a Phase III clinical trial (PLUS-1), is designed to be as efficacious as pharmaceuticals, less invasive than the surgical interventions, and without the sexual side effects seen with existing treatments.